Naba Alsaha Medical Services Company SJSC

Naba Alsaha Medical Services Company SJSC maintains a debt-to-equity ratio of 0.55, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 6.26, suggesting strong short-term liquidity. However, the company's free cash flow is negative at -41,181,320 SAR, and capital expenditures are substantial at -77,328,870 SAR, indicating significant reinvestment in operations. Profitability metrics show a return on equity of 12.35% and a return on assets of 7.15%, which are in line with the industry's preferred metrics. These figures suggest the company is generating reasonable returns relative to its equity and asset base. However, the operating income margin of 15.3% is slightly below the cohort median of 16.8%, indicating potential inefficiencies in cost management. The company's revenue is split between two segments: medical services and pharmaceuticals. The medical services segment is the primary revenue driver, with the pharmaceutical segment contributing a smaller portion. Geographically, the company is heavily concentrated in Saudi Arabia, with no disclosed international operations. This concentration may expose the company to regional economic and regulatory risks. Looking ahead, the company is projected to see a 4.2% increase in revenue in the current fiscal year and a 3.8% increase in the next fiscal year. These growth rates are modest compared to the industry average of 5.5%, suggesting the company may face challenges in outpacing its peers. The company's recent financial performance shows a 2.1% year-over-year revenue growth, which is below the industry median of 3.9%. The company's risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates potential liquidity constraints. The company has not disclosed any imminent dilution events, and the dilution potential is currently low. However, the negative free cash flow and high capital expenditures may necessitate future financing, which could introduce dilution risk. Recent events include the company's 2023 annual report filing, which disclosed the financial snapshot and valuation metrics. No significant earnings call transcripts or regulatory filings were identified in the latest data. The company's recent performance and strategic direction are primarily reflected in its annual report disclosures.